Cart
sales@molnova.com
EP1-antagonist-1
CAS No. 851204-35-8
EP1-antagonist-1( EP1 antagonist 1 )
Catalog No. M26017 CAS No. 851204-35-8
EP1-antagonist-1 is an EP1 antagonist (pKi: 7.54; pIC50: 8.5).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 264 | Get Quote |
|
| 5MG | 404 | Get Quote |
|
| 10MG | 593 | Get Quote |
|
| 25MG | 888 | Get Quote |
|
| 50MG | 1251 | Get Quote |
|
| 100MG | 1692 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEP1-antagonist-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionEP1-antagonist-1 is an EP1 antagonist (pKi: 7.54; pIC50: 8.5).
-
DescriptionEP1-antagonist-1 is an EP1 antagonist (pKi: 7.54; pIC50: 8.5).
-
In Vitro——
-
In Vivo——
-
SynonymsEP1 antagonist 1
-
PathwayOthers
-
TargetOther Targets
-
RecptorCleavable
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number851204-35-8
-
Formula Weight470.14
-
Molecular FormulaC19H15BrCl2N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1cc(nn1Cc1cc(Br)ccc1OCc1ccc(Cl)cc1Cl)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
5-Hydroxymethyl-2-fu...
5-Hydroxymethyl-2-furancarboxylic acid (Sumiki's acid) is a naturally occurring human metabolite. Sumiki's acid was first identified in the urine of a leukemia patient who was excreting an abnormal amount of its glycine derivative. Sumiki's acid has been found to be a byproduct of the fungus Aspergillus and probably other species of fungi and yeast as well.
-
CDDO-3P-Im
CDDO-3P-Im, an analog of CDDO-Imidazolide, has a chemopreventive effect. It can reduce the size and severity of the lung tumors in the mouse lung cancer model.
-
FIDAS-5
FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.
